文献速递免疫规划

实体器官移植受者双倍剂量与标准剂量季节性流感疫苗的免疫原性与安全性随机对照试验

Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.
PubMed 文献 · Vaccine · 2018-09-01

DD组40%受者发生血清转换,SD组26%(P=0.174);DD组对全部病毒株达到血清保护的比例更高(88% vs 69%,P=0.048)。两组不良事件多为轻度,未观察到疫苗相关严重不良事件。

要点

  • 双倍剂量组对全部病毒株的血清保护率显著高于标准剂量组(88% vs 69%,P=0.048)。
  • 双倍剂量组疫苗应答率40%,标准剂量组26%,差异无统计学意义(P=0.174)。
  • 两组不良事件多为轻度,未观察到疫苗相关严重不良事件。

核心结论

  • 双倍剂量流感疫苗安全,可能提高移植受者的抗体应答;在高剂量疫苗不可及时,DD接种可作为替代选择。

主要发现

  • DD组40%受者发生血清转换,SD组26%(P=0.174)。
  • DD组88%受者对全部病毒株达到血清保护,SD组69%(P=0.048)。
  • 接种后几何平均滴度:H1N1为DD组131.9 vs SD组89.7(P=0.187),H3N2为DD组185.4 vs SD组138.7(P=0.182),流感B为DD组96.6 vs SD组68.8(P=0.081)。
  • 两组不良事件多为轻度,未观察到疫苗相关严重不良事件。

关键数值与推荐

  • 疫苗应答定义为接种后2周对至少一种病毒株发生血清转换。
  • 血清保护定义为血凝抑制滴度≥40。

临床怎么用

  • 在高剂量流感疫苗不可及时,可考虑对实体器官移植受者使用双倍剂量(30 µg)三价灭活流感疫苗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of vaccines with higher doses of antigen is an attractive strategy to improve the immunogenicity of influenza vaccination in transplant recipients. However, the effect of vaccination with a double-dose (DD) containing 30 µg of antigen in this population remains unknown. METHODS: We performed a randomized controlled trial to compare the immunogenicity and safety of DD (30 µg) vs. standard dose (SD, 15 µg) of a trivalent inactivated influenza vaccine in kidney and liver transplant recipients. Immunogenicity was assessed by hemagglutination-inhibition assay. Vaccine response was defined as seroconversion to at least one viral strain 2 weeks after vaccination and seroprotection as a titer ≥40. RESULTS: Sixty-three kidney and 16 liver transplant recipients were enrolled. Forty patients received the DD and 39 the SD vaccine. Overall, 40% of patients in the DD compared to 26% in the SD group (P = 0.174) responded to vaccine. In the DD arm, more patients were seroprotected to all viral strains after vaccination (88% vs 69%, P = 0.048). Post vaccination geometric mean titers of antibodies were 131.9 vs. 89.7 (P = 0.187) for H1N1, 185.4 vs. 138.7 (P = 0.182) for H3N2, and 96.6 vs. 68.8 (P = 0.081) for influenza B with the DD vs. SD. In both groups, most of the adverse events were mild and no vaccine-related severe adverse events were observed. CONCLUSION: Double-dose influenza vaccine is safe and may increase antibody response in transplant recipients. In this population, DD vaccination could be an alternative when high-dose vaccine is not available. NCT02746783.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mombelli M, Rettby N, Perreau M, et al. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. Vaccine. 2018. PMID: 30181045. doi:10.1016/j.vaccine.2018.08.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。